CJC-1295 vs MK-677 (Ibutamoren)
GHRH Analog · Growth Hormone Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
CJC-1295
A GHRH analog that sustains GH release for days via the DAC modification; injectable, once or twice weekly.
MK-677
An oral non-peptide ghrelin receptor agonist that triggers endogenous GH release in pill form; daily dosing.
CJC-1295
27 studies
2 human trials
Not FDA-Approved
MK-677
134 studies
24 human trials
Not FDA-Approved
What it does
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
How it works
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
How often
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
How strong
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
Main tradeoff
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
Best for
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
How to choose
A good fit for CJC-1295
- Research on GHRH receptor-mediated GH release with extended pharmacokinetics
- Research prioritizing minimal off-target hormonal and metabolic effects
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
A good fit for MK-677
- Research on oral GH secretagogue mechanisms versus injectable alternatives
- Research contexts where injection avoidance is a primary consideration
- Research comparing sustained ghrelin receptor activation with GHRH receptor activation
Consider both across time
CJC-1295 and MK-677 both raise endogenous growth hormone but through different receptors. CJC-1295 works through the GHRH receptor with minimal off-target effects; MK-677 works through the ghrelin receptor with metabolic trade-offs including appetite increase and potential glucose effects. The delivery difference (weekly injection versus daily pill) often drives the practical choice. Neither is FDA-approved. For a three-way comparison including the selective injectable ghrelin agonist, see MK-677 vs Ipamorelin vs CJC-1295.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation; Liver IGF-1 Production connects to IGF-1 Elevation
- Ghrelin Receptor (GHS-R1a)
- Ghrelin Receptor (GHS-R1a) activates Pituitary Somatotrophs
- Pituitary Somatotrophs connects to Growth Hormone Release
- Growth Hormone Release stimulates Liver IGF-1 Production
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form rather than injection.
Research Evidence
MK-677 has more extensive human trial data: multiple controlled studies (8 to 24 weeks) documenting GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements. CJC-1295 has Phase I/II pharmacokinetic data characterizing sustained GH release from the DAC modification, but development was halted before Phase III and clinical outcome data is limited. Neither compound has completed the Phase III trials required for FDA approval.
- 1.
If avoiding injections is a priority, MK-677 is the only oral option with meaningful human data.
- 2.
If appetite increase is a concern, CJC-1295 does not significantly stimulate appetite.
- 3.
If metabolic health markers need to stay clean (glucose, insulin), CJC-1295 has a more favorable profile.
- 4.
If the priority is the strongest available human evidence for GH elevation, MK-677 has more published data.
Key Limitations
- •No head-to-head trial comparing CJC-1295 and MK-677.
- •MK-677's metabolic effects (glucose, insulin) may limit its suitability for some users.
- •CJC-1295 DAC creates sustained GH elevation that may not be ideal for all applications.
- •Long-term outcome data comparing oral vs injectable GH optimization does not exist.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
MK-677 (Ibutamoren)
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Safety Comparison
CJC-1295 has the narrower published side effect profile: injection site reactions, water retention, and numbness reported in trials. MK-677 carries a broader metabolic side effect profile including appetite stimulation, potential blood glucose elevation, reduced insulin sensitivity, and water retention. The elderly hip-fracture study (Murphy 2008) was discontinued due to a congestive heart failure signal in that population. Neither compound has long-term human safety data.
CJC-1295
Limited but generally favorable safety data. Common side effects include injection site reactions, water retention, and numbness or tingling. No serious safety signals in published studies.
MK-677 (Ibutamoren)
More side effects than CJC-1295. Increased appetite is common and can be significant. May elevate blood glucose and insulin levels. Water retention and lethargy reported. Long-term metabolic effects need monitoring.
What the Research Suggests
MK-677 is the easier option to take and has more published human data. CJC-1295 is cleaner metabolically but requires injection. The choice often comes down to whether the convenience of oral dosing outweighs the metabolic trade-offs.